Home/Pipeline/CBI-1214

CBI-1214

Colorectal Cancer

Phase 1Active

Key Facts

Indication

Colorectal Cancer

Phase

Phase 1

Status

Active

Company

Cartography Biosciences

About Cartography Biosciences

Cartography Biosciences is a private, clinical-stage biotech founded in 2021 and based in San Francisco. The company has developed a proprietary technology platform that creates detailed maps of antigen expression across millions of cells from thousands of patient samples, aiming to overcome the target limitation in immuno-oncology. With a lead T-cell engager program (CBI-1214) now in Phase 1 trials for colorectal cancer and a strategic collaboration with Pfizer, Cartography is advancing a pipeline of antibody-based therapies. The company is backed by significant venture capital, including a $67 million Series B financing round.

View full company profile

Therapeutic Areas

Oncology

Other Colorectal Cancer Drugs

Drug	Company	Phase	Status
CY-101 + Pembrolizumab	Cytovation	Phase 1/2	Initiate 1H-26
M9140	Merck KGaA	Phase 1/2	Active
Repositioned/Rerouted API	Reponex	Not Specified	Active
Leronlimab	CytoDyn	Phase 2	Phase in progress
EGFR inhibitor	Acellera	Pre-clinical	Hit Identification
Cannabics® RCC-33	CNBX Pharmaceuticals	Preclinical	Preparation of Pre-IND Meeting Package
VCR-036	Vicero Bio	Preclinical	Active
QL335	QLSF Biotherapeutics	Phase 1	Active
Colorectal Cancer Detection Partnership	Daisy Genomics	Research/Assay Development	Active
High Internalization ADC	Lytica Therapeutics	Preclinical	Active
Undisclosed Colorectal Program(s)	Tavanta Therapeutics	Phase 2	Active
KRAS AK™PCR Mutation Screen Kit	Akcell Biotech	Commercial	Active